Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · QuidelOrtho (QDEL)

QuidelOrtho posts $2.03 billion full-year net loss on $1.82 billion goodwill impairment

Negative Impact 4 of 5 earnings Written later

QuidelOrtho reported fourth-quarter 2024 revenue of $708 million, down from $743 million, and a GAAP net loss of $153 million. For the full year, revenue fell to $2.78 billion from $3.00 billion, and the net loss was $2.03 billion, driven by a $1.82 billion goodwill impairment charge. The company also issued 2025 guidance of $2.60 billion to $2.81 billion in revenue and $575 million to $615 million in adjusted EBITDA.

Key points

  • Q4 2024 revenue was $708 million versus $743 million; GAAP diluted loss was $2.28 per share versus earnings of $0.10 per share
  • Full-year 2024 GAAP diluted loss was $30.16 per share, including a goodwill impairment charge of approximately $1.82 billion
  • Full-year 2024 adjusted diluted EPS was $1.85, down from $4.13; adjusted EBITDA was $543 million versus $723 million
  • 2025 guidance: total revenue $2.60 billion to $2.81 billion, adjusted EBITDA $575 million to $615 million, adjusted diluted EPS $2.07 to $2.57

The filing

CompanyQuidelOrtho (QDEL)
Form8-K, current report
Filed with the SECFeb 12, 2025, 4:06 PM ET
Accession number0001906324-25-000031

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:07 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 12, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.